$CNSY News
Last published 1d ago
- 1d agoCNSYCerenome Appoints Director Ron Andrews as Chief Business OfficerGlobeNewswireExecutive board member with 35-plus years of diagnostics leadership and more than $15 billion in strategic exits to drive CNSide® growth and strategic partnerships
- 1w agoCNSYCerenome Secures National In-Network Agreement with Aetna for CNSide®GlobeNewswireCerenome now contracted with approximately 85% of private payers in the US, representing approximately 190 million covered lives First national CNSide payer agreement to include both tumor cell enumeration and
- 1w agoCNSYCerenome Completes Enrollment in Phase 2 ReSPECT-GBM Trial of REYOBIQ™ in Recurrent GlioblastomaGlobeNewswireTopline data expected in mid-2027 Previously reported interim Phase 2 data showed a 63% improvement in median overall survival versus standard of care in recurrent glioblastoma (13 months vs. 8 months) HOUSTON,
- 2w agoCNSYCerenome to Present Interim Clinical Update on the ReSPECT-LM Trial of Multiple REYOBIQ™ Doses in Leptomeningeal MetastasesGlobeNewswireCompany to provide latest clinical trial data and highlight evolving approaches to leptomeningeal metastases diagnosis and treatment in a company sponsored symposium 2026 SNO Annual Meeting to be held on November 12-15
- 3w agoCNSYCerenome Announces New Dual Mechanism of Action Featuring Lethal DNA Damage and Beneficial Immunomodulation Supporting Lead Investigational Drug REYOBIQ™GlobeNewswireFindings suggest a dual mechanism of action for REYOBIQ against cancer cells New findings revealed potential dual mechanism as combinations with checkpoint blockade further enhanced REYOBIQ therapeutic action in
- 1mo agoCNSYCerenome Secures In-Network Agreement with Florida Blue for CNSide® CSF Tumor Cell Enumeration and Molecular Profile TestsGlobeNewswireFirst CNSide payer agreement to include CNSide’s new CSF Molecular Profile tests alongside tumor cell enumeration Expands CNSide contracted payer access to approximately 164 million covered lives HOUSTON, Oct. 08,
- 1mo agoPSTVCNSYWHY BRAIN CANCER HAS BEEN LEFT BEHIND FOR 50 YEARS | CERENOME CEO MARC HEDRICK & RUSSELL BRADLEY - CERENOME INCEarnings Call TranscriptsWelcome back to the Biohub podcast by Avetix. Today, I'm joined by two leaders working at the intersection of CNS oncology, diagnostics, targeted radiotherapeutics, and brain cancer care. First, Mark Hedrick, CEO of Sere
- 1mo agoPSTVCNSYCERENOME: CNSIDE BUSINESS UPDATE - CERENOME INCEarnings Call TranscriptsGood morning and welcome to the Serenome third quarter 2026 business update conference call. At this time, all participants are in a listen-only mode. After management's prepared remarks, we will open the call for questi
- 1mo agoCNSYCerenome Appoints Samantha Fowlkes as Vice President and Head of Commercial Sales, CNSide Diagnostics DivisionGlobeNewswireHOUSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Cerenome, Inc. (NASDAQ:CNSY) ("Cerenome" or the "Company"), today announces the appointment of Samantha
- 2mo agoCNSYPSTVCerenome Announces Up to $20 Million Financing Facility with Royalty-Based RepaymentGlobeNewswireCapital will support continued CNSide® commercial scale-up and development Initial tranche of funding provided at closing with future tranches linked to milestones Forecasted cash runway now into 2028 HOUSTON, Sept.
- 2mo agoCNSYPSTVCerenome Highlights Presentations at the 2026 SNO/ASCO CNS Metastases Conference Demonstrating Progress in Both Therapeutics and Diagnostics Business LinesGlobeNewswirePharmacokinetic and dosimetry findings of Reyobiq from RESPECT-LM single dose study shows broad CSF compartmental distribution and on target drug activity. Update on ongoing multidose leptomeningeal metastases trial
- 2mo agoPSTVCNSYCERENOME (NASDAQ: CNSY) REBRAND, FORMERLY PLUS THERAPEUTICS | FINTECH TV EXCLUSIVE - CERENOME INCEarnings Call TranscriptsSerenome, formerly known as Plus Therapeutics, is rebranding as it moves from single drug developer to a full CNS cancer platform, combining therapeutics, diagnostics, and AI. The new ticker is CNSY, and it takes effect
- 2mo agoCNSYPSTVCerenome Reports Second Quarter 2026 Financial Results and Business UpdateGlobeNewswireHOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (NASDAQ:CNSY) ("Cerenome" or the "Company"), a CNS oncology company advancing an integrated platform that combines precision diagnostics,
- 3mo agoCNSYPSTVCerenome Secures In-Network Agreement with Health Care Service Corporation, Expanding CNSide® Contracted Coverage to Over 150 Million Covered LivesGlobeNewswireHOUSTON, Aug. 13, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), announced today that it has signed an
- 3mo agoCNSYPSTVCerenome Selects XiFin Empower RCM for Revenue Cycle Management and Clearinghouse Services for CNSide PlatformGlobeNewswireHOUSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Cerenome, Inc. (NASDAQ:CNSY) ("Cerenome" or the "Company"), announced today that it has selected XiFin,
- 3mo agoPSTVCNSYCerenome Launches as an Integrated CNS Oncology CompanyGlobeNewswireHOUSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) (the "Company"), today announces that its corporate rebrand to Cerenome will be completed as scheduled. Effective August 3,